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The Role of Tocilizumab in Treatment of a Patient with COVID-19: 
a Case Report 
 
 




SARS-CoV-2 (COVID-19) is an infectious disease caused by a new discovered 
Coronavirus. Most people infected with the COVID-19 virus recover without 
special treatment and experience mild to moderate respiratory disease. In the 
elderly and people with underlying diseases such as cardiovascular disease, 
diabetes, chronic respiratory disease and cancer, there is a higher risk of 
developing the severe form of the disease. So far, no specific drug has been 
found to prevent or treat COVID-19. A 52-years old diabetic man with COVID-
19 was admitted to Ayatollah Rouhani Hospital Babol, Iran. After 12 days of 
hospitalization and treatment, with respiratory distress and oxygen saturation 
level to 60%, he was transferred to the intensive care unit. After receiving a 400 
mg dose of actemra or tocilizumab, the patient became severely dehydrated and 
the oxygen saturation level reached over 90% within a few hours, and 8 days 
after receiving tocilizumzb (TCZ; Actemra), the patient was suffering from 
complications of pneumonia. So far, there have been reports of improvement in 
patients with Coronavirus (COVID-19) with severe actemra or tocilizumab. 
Typically the COVID-19 virus appears to be able to be cause the over-immune 
reaction and typically the cytokine storm, which often includes IL-6, therefor 
may be IL-6 antagonist improves patients’s condition. 
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Introduction 
A number of unexplained cases of pneumonia were 
reported in Wuhan, Hubei Province, China, In 
December 2019. On January 12, 2020, the World 
Health Organization named the virus 2019 novel 
corana virus 2; belonging to the Coronaviridae family. 
(1, 2). Coronaviridae is a family of single-stranded, 
enveloped and positive-sense RNA virus. In human, 
Coronavirus can cause respiratory tract infection.  
SARS-CoV-2 (COVID-19), Coronavirus Acute 
Respiratory Syndrome (SARS-CoV) and Coronavirus 
Middle East Respiratory Syndrome (MERS-CoV)) are 
members of the coronavirus family that can infect 
humans and SARS-CoV-2 is the seventh member of 
this family (3). The fever, cough, and fatigue were the 
most common symptoms in patients with COVID-19. 
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A relatively small percentage of involving patients 
were asymptomatic. 
Quantitative reverse transcriptase polymerase 
chain reaction (RT-PCR) to detect the SARS-CoV-2 
nucleic acid is the primary and most important method 
for diagnosis (4). Most patients showed normal 
leukocytes, lymphopenia, increased C-reactive protein 
(CRP) and Erythrocyte sedimentation rate (ESR). 
Bilateral lung involvement was common (5). 
For some patients with the new SARS-CoV-2 
(COVID-19), their immune system is stimulated and 
launches a comprehensive attack known as the 
Cytokine storm. This over-reaction of the immune 
system can damage the tissue and cause the patient to 
die (6).  
Tocilizumab (TCZ; Actemra) is a drug 
approved for the treatment of rheumatoid arthritis and 
young rheumatoid arthritis.It blocks the interleukin 6 
cell receptor, cytokine, which can cause dangerous 
inflammatory waterfalls (7). There are reports of the 
use of tocilizumab as an effective treatment option in 
patients with COVID-19 (8, 9). 
In this report, the experience of treatment with 
tocilizumab will be expressed in a corona patient. 
 
Case Report 
A 52-year-old diabetic patient with controlled 
blood sugar metformin was admitted to rohani Babol 
Hospital with fever, sweating, shortness of breath, and 
cough. After CT scan of the lungs and multiple lesions 
of ground-glass opacities, he was hospitalized with 
corona diagnosis and the necessary samples were taken 
from the respiratory system to confirm COVID-19 
disease for the patient (Figure 1). The patient's oxygen 
saturation level was 80% upon arrival. Patients 
underwent Tamiflu, Chloroquine, Lopinavir / 
Ritonavir (Kaletra) and Vancomycin, Levofloxacin 
and Ribavirin, oxygen therapy and other symptomatic 
treatment for 12 days. 
On the twelfth day of hospitalization, the patient 
developed respiratory distress despite the above-
mentioned treatments and with an oxygen level of 
60%, it was transferred to the intensive care unit. The 
patient's condition at the time of entering ICU was as 
discussed in the following lines. 
For the patient, NIV (Non-invasive ventilation) 
was assigned with positive end-expiratory pressure 
(PEEP) = 8 and pressure support = 18 the next day, it 
was oxidized to 82% oxygen level and subjected to 
ACMV ventilation mode After one day of invasive 
ventilation, the patient's oxygen saturation level was 
between 65 and 80 percent, so tocilizumab was 
injected with a 400 mg vial for the patient. Four hours 
after the injection of tocilizumab, the patient's oxygen 
saturation level reached 90% and then the patient 
recovered within a few days. The patient's tests were 
compared before and after receiving tocilizumab in 
Table 1. 
On the eighth day after administration of 
tocilizumab, despite continued extensive antibiotic 
therapy, endotracheal tube secretion was increased and 
became purulent. The patient's tests also preferably 
included leukocytosis, neutrophil. There was also lobar 
pneumonia in the patient's chest and CT scan (Figure 
2). Acinetobacter patient sensitive to colchicine was 
found in the sputum collection and the patient was 
treated. 
 
Figure 1.  Chest x-ray and chest CT scan before TCZ 
administration. 
 
Figure 2.  Chest x-ray and chest CT scan two weeks after 
TCZ administration. 
 
Figure 1. Chest x-ray and chest CT scan before TCZ 
administration.. 
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On the 19th day, the patient was hospitalized and treated in the intensive care unit with partial respiratory 
Table 1: Patient’s laboratory results Before and after tocilizumab treatment 
 
After TCZ (2 week) Before TCZ  
23900 7000 WBC count×109  
88.9 76 Neutrophil percent 
5.3 19,1200 Lymphocyte percent  
280 266 Platelet count×109 
96 125 Hemoglobin, g/L 
0.8 1 Creatinine, mmol/L 
35 14 Blood Urea Nitrogen (BUN) 
mg/dL 
24 38 Alanine Transaminase (ALT); U/L 
22 49 Aspartate Transaminase (AST); 
U/L 
140 119 Blood Sugar level (mg/dL) 
105 188 Serum Creatin Phosphokinase 
(CPK) U/L 
15 12 Prothrombin time (PT) 
32 31 Activated Partial Thromboplastin 
Time (aPTT) 
1.4 1 International Normalized Ratio 
(INR) 
571 663 Lactate dehydrogenase, U/L 
121 91 C-reactive protein, mg/L 
- 45 Erythrocyte Sedimentation Rate 
(ESR) 
135 132 Serum level of Sodium ion 
4.7 3.9 Serum level of Potassium ion 
2.5 1.9 Serum level of Magnesium ion 
0.9 - Serum level of Pro-calcitonin 
(ng/mL) 
 
Amri Maleh et al.                                     The Role of Tocilizumab in Treatment of a Patient with COVID-19: a Case Report 
 Journal of Cellular & Molecular Anesthesia (JCMA) 
120 
recovery and underwent non-invasive adjuvant 
ventilation for five days and was discharged from the 
ICU with an oxygen saturation level above 92% in 
room air without respiratory distress and shortness of 
breath. 
Discussion 
In this study, the therapeutic effect of a dose of 
TCZ in a critically ill patient with COVID-19 and its 
complications has been reported. In this patient, the 
level of acute phase reactors decreased and the patient 
gradually reached a stable state with a gradual decrease 
in interleukin 6 after TCZ administration. 
The logical reason for the effect of TCZ in 
patients with COVID-19 is based on the role of 
interleukin 6 in this disease (6). 
In a study about immunopathology of COVID-
19 suggested that the pathogenic GM-CSF+ Th1 cells 
and inflammatory CD14 + CD16+ monocytes caused 
excessive activated immune response and this response 
was linked to severe lung pathology in COVID-19 and 
It has been suggested that a monoclonal antibody 
targeting the IL-6 receptor may be effective in treating 
coronavirus pneumonia (12). 
The effect a dose of TCZ seen in this patient was 
also seen in seriously ill patients with about 10 times 
elevated IL-6, and patients with higher level of IL-6 
benefited from repeated TCZ treatment and a single 
dose of TCZ, despite concomitant use of 
glucocorticoids, failed in patients with critical illness 
(8). 
However, complications of pneumonia were 
seen in this patient, and the patient underwent 
treatment for this complication in accordance with the 
collection of secretions. However, an increased risk of 
infections has been reported in tocilizumab. In a meta-
analysis, patients with rheumatoid arthritis who 
underwent monotherapy with the tocilizumab had at 
least one more infection than the control group and 
having at least one serious infection in these patients 
did not have a statistically significant difference (10). 
Other side effects have been reported in the 
tocilizumab, such as medication-related osteonecrosis 
of the jaw in patients with rheumatoid arthritis under 
treatment tocilizumab alone (11) or an increase in some 
laboratory markers such as lipids and liver function test 
and a decrease in the number of neutrophils in the 
blood test of these patients. There was no significant 
increase in the incidence of malignancy, tuberculosis, 
or hepatitis associated with the use of tocilizumab (10), 
which was not observed in our patient requiring a 
longer test check than receiving the tocilizumab.  
 
Conclusion 
In conclusion, the present study suggested that 
tocilizumab can be beneficial for critically ill patient 
with COVID-19, but should also consider the side 
effects of the drug. 
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